Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.

Carla BastidaVirginia Ruiz-EsquideMariona PascalAurelia H M de Vries SchultinkJordi YagüeRaimon SanmartíAlwin D R HuitemaDolors Soy

Published in: British journal of clinical pharmacology (2018)

Our study provides evidence to support fixed dosing of intravenous tocilizumab in rheumatoid arthritis patients since it reduces variability in tocilizumab exposure among weight categories compared to the current weight-based dosing approach.

Keyphrases

rheumatoid arthritis patients
disease activity
rheumatoid arthritis
systemic lupus erythematosus
body mass index
ankylosing spondylitis
weight loss
juvenile idiopathic arthritis
physical activity
high dose
weight gain
interstitial lung disease
low dose